Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Jamari 40 - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Jamari 40

Approved

STANDARD

Jamari 40

Globela Pharma Private Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 168ee9b357237cbe
Company: Globela Pharma Private Limited
Type: Standard

Approval Details

Approval Id: 168ee9b357237cbe
Drug Approval Philippines Name: Jamari 40
Product Name: Jamari 40
Registration Number: DRP-10475-03
Brand Name: Jamari 40
Generic Name: Telmisartan
Dosage Form: Tablet
Dosage Strength: 40 mg
Manufacturer: Globela Pharma Private Limited
Importer: AMB HK Enterprises Inc.
Distributor: PhilRx Pharma Inc.
Issuance Date: 24 March 2022
Expiry Date: 30 September 2026
Pharmacologic Category: Angiotensin II Receptor Blocker
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

168ee9b357237cbe

Type

Standard

Back to Philippines FDA Approvals